AstraZeneca Pharmaceuticals LP Senior Brand Manager in Australia
Senior Brand Manager, Immuno-Oncology
AstraZeneca has a deep-rooted heritage in Oncology and offers a quickly growing portfolio of new medicines that has the potential to transform patients’ lives and the Company’s future. With at least six new medicines to be launched between 2014 and 2020 and a broad pipeline of small molecules and biologics in development, we are committed to advance New Oncology as one of AstraZeneca’s five Growth Platforms focused on lung, ovarian, breast and blood cancers. In addition to our core capabilities, we actively pursue innovative partnerships and investments that accelerate the delivery of our strategy, as illustrated by our investment in Acerta Pharma in haematology.
By harnessing the power of four scientific platforms - Immuno-Oncology, the genetic drivers of cancer and resistance, DNA Damage Response and Antibody Drug Conjugates - and by championing the development of personalised combinations, AstraZeneca has the vision to redefine cancer treatment and one day eliminate cancer as a cause of death.
AstraZeneca’s path to leadership with its developing Immuno-Oncology franchise has delivered two critical advances - Imfinzi (durvalumab) has gained FDA approval for second line bladder cancer, and results for PACIFIC have also been announced this week. AZ have leap frogged its competitors with significant results for Imfinzi in locally advanced unresectable (Stage III) NSCLC, as maintenance therapy following chemoradiation.
This is a first in class result.
Our Oncology Business Unit has delivered two launches already in the last two years – Lynparza and Tagrisso have paved the way for AstraZeneca to feature as the market leading company in the treatment of ovarian and lung cancers. Hundreds of patients have already benefited from these treatments due to our innovative diagnostics and access programs.
We believe that everyday counts when a patient has cancer, and are passionate about bringing these medicines to Australia as quickly as possible.
Would you like to be a part of the leadership race in Immuno-Oncology? Our IO franchise will encompass bladder, lung and head & neck cancers in the short term, leading into expanded tumour types and earlier diseases in the mid to long term.
As our new IO Senior Brand Manager, you will be responsible for leading the commercial strategy for selected segments of the IO Franchise, with an immediate focus on impending launch activities. You will provide launch leadership & innovation, and drive launch success that truly delivers for patients, healthcare providers and AstraZeneca. Your demonstrated experience, along with an entrepreneurial approach will set you up for success.
You will be a dynamic and experienced Oncology marketer with an innovative spirit and a passion for delivering the best treatment possible for patients with cancer. You will work alongside colleagues who are passionate about patient outcomes, and are collectively driven by an entrepreneurial spirit.
Pharmaceutical experience in Oncology at senior marketing/commercial level would be highly advantageous
Experience in working within cross-functional business units
Experience with solid, haematological and/or biological preparations
In depth understanding of Hospital and specialty care environments
In depth understanding of local healthcare system pricing and reimbursement
Diagnostics experience and implementation of biomarker strategy
Experience in functions such as launch management, launch coordination or project management preferable
Clear evidence of innovation leading to success
Strong focus on effective decision making and results
Exceptional team player
Degree level qualification in science/medicine
AstraZeneca is an equal opportunity employer. AstraZeneca will consider all qualified applicants for employment without discrimination on grounds of disability, sex or sexual orientation, pregnancy or maternity leave status, race or national or ethnic origin, age, religion or belief, gender identity or re-assignment, marital or civil partnership status, protected veteran status (if applicable) or any other characteristic protected by law.
Applications close Friday 2nd June